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Summary Site of first recurrence, disease-free interval (DFI), female sex steroid receptors, ploidy
measurements as well as histological grading have been analysed as potentially valuable predictive factors in
313 cases of recurrent breast cancer. Univariate and multivariate analyses show histological grading, site of
recurrence and disease free interval to be useful prognostic variables when assessing prognosis once disease has
recurred. High concentrations of oestrogen receptors (ER) were found in patients with bone metastases,
whereas lower concentrations of ER were related to visceral recurrences. Ploidy measurements failed in this
study to give any predictive information once disease recurred.
Nodal involvement, tumour size, histological malignancy
grade and nuclear grade (Fisher et al., 1980, 1983, 1984;
Bloom, 1957; Wallgren et al., 1976; Blanco, 1980) as well as
oestrogen (ER) and progesterone (PR) receptor
measurements (Osborne et al., 1980, Blamey et al., 1980;
Blanco et al., 1984) and DNA flow cytometric analyses (Cor-
nelisse et al., 1987; Kallioniemi et al., 1987, 1988) are the
most important parameters used for the prognostic evalua-
tion of primary breast cancer. However, the value of these
prognostic factors, in cases of recurrent breast cancer, to
define post-relapse survival is not well established.
Although observations on prognostic determinants
influencing the behaviour of metastases from breast cancer
are scarce, some information on the behaviour of such metas-
tases emerges from evaluations of efforts at therapy in
different subsets of patients. Thus a significant correlation
has been found between the dominant site of recurrence and
the final outcome of the disease. A poor prognosis for liver
metastases, visceral and multiple involvement, as well as for
brain metastases, have been proved repeatedly (Fey et al.,
1981; Nash et al., 1982; Valagussa et al., 1979; Nikkanen,
1981; Di Stefano et al., 1979; Davidson et al., 1984), while
better prognoses have been found for bone and soft tissue
metastases (Hietanen, 1986; Clark et al., 1987). One impor-
tant parameter reflecting the aggressiveness of the disease is
the time from diagnosis to the appearance of the recurrence.
This parameter has repeatedly proved to be one of the most
useful for assessing the behaviour ofthe disease (Cutler et al.,
1969; Devitt et al., 1971; Pater et al., 1981; Hietanen, 1987).
It has been found more recently that recurrences among
ER-negative patients tend to be in the viscera, soft tissues
and brain, whereas ER-positive patients are more likely to
have recurrences in bone (Stewart et al., 1981; Clark et al.,
1987). This relation between recurrences at specific sites and
ER could not be confirmed by other authors (Kamby et al.,
1986). This report seeks to identify prognostic determinants
that rule the behaviour of recurrences stemming from breast
cancer. The selected prognostic variables for this study were:
(1) site of the first recurrence, (2) disease-free interval (DFI),
(3) primary ER and PR measurements related to site of
recurrence and survival, (4) primary tumour ploidy
measurements and (5) histological grading related to post-
relapse survival.
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Patients and methods
The data for this study comprise 613 cases of histologically
verified primary mammary carcinomas treated between June
1976 and December 1981 in Oulu and Tampere University
Central Hospitals. All those cases with known ER and PR
determinations and a complete follow-up were selected.
Bilateral and male breast cancer patients were excluded. The
clinical follow-up took place every 2-3 months during the
first 2 years, and every 4-6 months thereafter. A clinical
evaluation, as well as blood biochemistry, was done routinely
during follow-up. No other regular tests, such as bone scans
or abdominal ultrasounds, were done, unless patients became
symptomatic or other signs of disease recurrence were pres-
ent. All the living patients were traced up to December 1985.
The types of primary treatment are presented in Table I.
During this period a proportion of patients with stage II
and III breast cancer received adjuvant chemotherapy
(CMF). The proportion of patients receiving hormonal
adjuvant therapy (tamoxifen) was small. ER and PR were the
major criteria for selection of treatment relapse. However,
with progression of disease, many hormonal and cytostatic
schedules were used, as well as irradiation, making the
overall evaluation of treatment regimens difficult. The sites of
recurrence were divided into three categories: (1) local recur-
rence, comprising skin and subcutaneous metastases, regional
lymph nodes, nodes of the neck including those in the con-
tralateral region and enlarged mediastinal lymph nodes con-
firmed by X-ray; (2) bone, osteoblastic and lytic or mixed
lesions confirmed by X-ray; and (3) visceral, liver deposits
confirmed by ultrasound, lung and pleural metastases
confirmed by X-ray and, provided that pleural effusions were
confirmed by histological or cytological analysis, brain
metastases detected by brain scans and CT, when suggested
by neurological signs. The evaluation of the site of metastasis
made here takes into account the site of first recurrence.
Table I Primary treatment in 613 cases of breast cancer
Surgery
Simple mastectomy 191
Extended simple mastectomy 396
Tumorectomy 12
None 14
Postop. irradiation 396
None 217
Adj. cytostic therapy 73
None 540
Adj. Hormonal therapy 20
None 593
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The methods used to evaluate ER and PR have been
reported elsewhere (Vihko et al., 1980). In order to evaluate
the relationship between the concentration of ER and PR in
the primary tumour and the first site of metastases, the cases
were arbitrarily divided into groups according to their ER
and PR concentrations as follows: the first group contained
cases in which ER was considered negative (<3 fmol mg-'
cytosol protein), the second had concentrations between 3
and lOOfmolmg'I cytosol protein, and the third group had
concentrations above 100 fmol mg-' cytosol protein. The PR
groups were similarly divided, the first group containing
PR-negative cases (<10 fmol mg ' cytosol protein), the
second group, cases with PR concentrations between 10 and
100 fmol mg-' cytosol protein, and the third group with high
concentrations of PR, > 100 fmol mg' cytosol protein.
Histological malignancy grading was performed according
to the recommendations stated by the Classifications of
Tumours of the Breast (WHO, 1968).
DNA flow cytometric analysis was performed by process-
ing paraffin embedded primary breast tumour specimens as
previously described (Kallioniemi et al., 1987). This analysis
was performed in 226 cases.
Curves depicting survival from the first recurrence until
December 1985 were constructed using the Kaplan-Meier
(1958) product limit estimation. Similarities between the sur-
vival curves for the different groups were tested using the
log-rank test (Mantel, 1966). Multivariate analysis was tested
with Cox's proportional hazard model. Computations were
performed using programs from the SAS statistical package
on an IBM 3083 computer.
Results
Site ofrecurrence
Of the 613 cases with primary breast cancer, 313 developed a
recurrence after primary treatment. The highest frequency
was observed in soft tissue, mainly in the skin (Table II), and
the next most frequent site was the viscera, whereas the brain
was rare as the first site of recurrence, accounting for only
1.9% of all the recurrences observed. The worst survival
rate was found in patients with visceral recurrences, with a
median survival of 12 months, followed by bone metastasis,
with a median survival of 19 months. The best prognosis was
found for soft tissue recurrence, with a median survival of 32
months. The differences in the curves are statistically highly
significant (P<0.0001) (Figure 1).
Regardless of the initial site of recurrence, ER-positive
patients survived longer than ER-negative patients, and a
similar relationship was also noted among patients with PR
positive tumours compared to PR-negative patients. The
differences observed in the survival curves, when related to
ER, do not quite reach statistical significance, but the sur-
vival difference for soft tissue and bony recurrence sites,
when related to PR, was statistically significant (Figures 2
and 3).
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Figure 1 Survival after first recurrence by site ofrelapse. Median
survival: soft tissue (a) 32 months, bone (b) 19 months and
viscera (c) 10 months (P = 0.001).
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Disease-free interval (DFI)
The patients with recurrent malignancies were divided into
three groups: disease-free survival less than 1 year, 1-3 years
Table II First site of recurrence in 313 cases of breast cancer
Site No. ofcases %
Skin 90 29
Bone 75 24
Lung 60 19
Lymph nodes 52 17
Liver 25 8
Brain 6 2
Other 5 1
Total 313 100
Months
Figure 2 Survival after first recurrence by site of relapse. ER +
patients survived longer than ER- patients regardless of the site
of recurrence. Median survival times were 40 vs 24 months for
soft tissue (a, P = 0.05), 20 vs 14 months for bone (b, P = 0.1)
and 19 vs 10 months for viscera (c, P = 0.02).
and over 3 years. A longer survival period was observed in
those patients who also had a longer DFI. The difference
between the survival rates of these groups was highly sig-
nificant (P<0.0001) (Figure 4).
Oestrogen andprogesterone receptors
The differences in the proportion of ER-positive and PR-
positive cases between the groups defined according to the
first site of metastasis were not statistically significant,
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Figure 4 Disease-free survival < I year, 1-2 years, >3 years
(P =0.0001).
of metastases, it was observed that the lowest concentrations
were found in those primary tumours which recurred in
visceral organs, whereas the highest values were found in
cases of bone recurrence. The difference between the ER
values, when related to the site of metastasis, was statistically
highly significant (P<0.0001) (Table III), whereas the
differences between the PR values did not reach this level of
statistical significance.
PR+
50 60
Figure 3 Survival after first recurrence by site of relapse. PR +
patients survived longer than PR- patients. Median survival
times were 50 vs 25 months for soft tissue (a, P = 0.006), 23 vs 18
months for bone (b, P= 0.005) and 17 vs 8 months for viscera (c,
P=0.1).
although a high proportion of cases with ER and PR-
negative were in the group with visceral metastasis, especially
involving the liver and the lung, while a greater proportion of
ER and PR-positive had recurrences in bone. A slight
difference existed between the ER-negative and positive cases
when related to soft tissue recurrences.
Evaluation of the relation between the concentration of
female sex steroid receptors and the primary site of metas-
tasis showed that the proportion of visceral metastases
decreased proportionally with increasing concentrations of
female sex steroid hormone receptors, while the proportion
of bone metastases was highest in those cases with the
highest values for female sex steroid hormone receptors.
When the values for ER and PR were related to each pattern
DNAflow cytometric analysis
The frequency of metastases was significantly lower
(P<0.0001) among the DNA-diploid cases (29%) than in
the aneuploid group (57%). When DNA ploidy was related
to the site of first metastasis no consistent correlation
between the proportion of DNA-aneuploid tumours was
found (Table IV). Furthermore, no significant difference was
found between the DNA-diploid and DNA-aneuploid cases
in terms of their survival curves (Figure 5).
Histological malignancy grading
Histological grading has been considered, despite its limita-
tions, as a valuable biological criterion for prognosis in
primary breast cancer. Therefore the evaluation of histo-
logical grading was included in this study to define its impor-
tance to recurrent breast cancer.
Table IV DNA ploidy in 226 cases of primary and recurrent breast
cancer
Recurrences (%)
No. ofcases NED (%) Viscera Bone Soft
Diploid 89 71 9 4 16
Aneuploid 137 43 22 10 25
Table III Oestrogen and progesterone receptor concentrations related to first site of
recurrence in breast cancer
ER<3fmol ER 3-100fmol ER> 100fmol Mean Median
Site No. % No. % No. % Total value value
Bone 17 20 27 18 24 42 68 127 46.0
Soft tissues 35 41 76 50 23 42 134 67 11.5
Viscera 34 39 48 32 9 26 91 43 8.0
p<0.0001
PR<lOfmol PR 10-JOOfmol PR>1OOfmol Mean Median
No. % No. % No. % Total value value
Bone 28 21 17 20 23 32 68 109 27.0
Soft tissues 56 41 45 52 33 46 134 75 27.0
Viscera 51 38 24 28 16 22 91 94 5.0
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Figure 5 Survival after first recurrence by ploidy of the primary
tumour. Diploid tumours (d), aneuploid tumours (a) (P = not
significant).
The evaluation of histologial grading was possible in 234
out of the 313 cases included in this study. Only 18 grade I
tumours were found, whereas 76 cases were recorded as
grade II. The vast majority of cases with recurrent breast
cancer, 140 in total, belong to grade III. The post-relapse
survival curves, when related to histological grading, show
that patients with grade I tumours survive longest after
recurrence of their disease, whereas the shortest survival after
relapse was found for patients having grade III lesions.
The survival of patients with grade II tumours lay in
between. The differences between the survival curves were
statistically significant (P = 0.0001) (Figure 6).
Multivariate analysis
A multivariate analysis of the prognostic variables was
intended. However, the proportion of single variables used in
this material does not fit well with the Cox's proportional
hazard model, mainly because of the unequal number of
cases for the evaluation of each variable. The number of
cases for the ploidy multivariate analysis was considerably
smaller than the number of other variables and therefore
ploidy was not included in the multivariate analysis. To
obtain a greater number of cases for this analysis, his-
tological grades I and II were arbitrarily pooled as were bone
and viscera groups for first site of recurrence. After these
modifications to the material the multivariate analysis shows
that histological grading, recurrence-free survival time and
site of primary recurrence are the most important predictive
variables in recurrent breast cancer (Table V).
Discussion
The present analysis of 313 cases of breast cancer which
subsequently developed metastases shows that patients with
soft tissue recurrences had a significantly better prognosis
than those with bone metastases, and that patients with
visceral metastases had the worst prognosis. The better prog-
nosis for soft tissue recurrences is in general attributed to the
earlier detection and better management or less aggres-
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Figure 6 Survival after first recurrence by histological malig-
nancy grade. Grade I (a), grade 11 (b), grade III (c) (P = 0.0001).
siveness of such recurrences, whereas liver metastases, which
are more common among histologically aggressive tumours,
lead to a rapid progression of the disease (Cutler et al., 1969;
Hietanen, 1987). Another cause for the shorter survival of
cases with visceral metastases may be the rapid impairment
of the affected organs and their poor response to treatment
(Hietanen, 1987).
A longer recurrence-free period and a better overall sur-
vival rate have been observed among breast cancer patients
with postive ER and PR (Bishop et al., 1979; Osborne et al.,
1980; Blamey et al., 1980; Blanco et al., 1984; Thorpe et al.,
1986). This finding has been regarded as an indication of a
better response to hormonal therapy among such patients. A
better survival rate was also seen here for the ER-positive
patients than for the ER-negative ones, regardless of the site
of recurrence. ER status also emerges as a prognostic
variable upon recurrence of the disease, as described by
Clark et al. (1987). However, the value of PR as a prognostic
determinant in recurrent breast cancer is nevertheless shown
here to be stronger than that of ER.
The disease-free interval following the first recurrence is of
great significance for survival (Cutler et al., 1969; Aberzik,
1986; Hietanen, 1987), although there are also some reports
to the contrary (Rosenman & Perrone, 1984). The present
patients, with a recurrence detected during the first year after
diagnosis of the primary disease, fared extremely poorly com-
pared with those whose recurrence was detected during the
second year or later following diagnosis of their disease.
A number of authors have suggested that ER-positive
tumours are more likely to recur in the bone and ER-
negative ones in the viscera and the brain (Singhakowinta et
al., 1976; Stewart et al., 1981; Clark et al., 1987). The present
results also point to a greater proportion of ER and PR-
negative patients having recurrences in the lung and liver
while those ER and PR-positive patients more often had
recurrences in bone. Furthermore, visceral metastases
appeared more frequently in the group with no ER or a low
ER content, while bone recurrences were found in the group
in which the highest ER values were found.
This relationship was less marked for PR. The relationship
between sex steroid hormone receptors and the site of the
Table V Multivariate analysis in recurrent breast cancer
95% confidence
Relative risk interval of
ofdeath relative risk P
Histological malignancy grading 1.7 1.2-2.4 0.0039
Recurrence free survival 0.98a 0.97-0.99 0.0029
Site of first recurrence 2.4 1.7-3.3 0.0000
aContinuous covariate.146 G. BLANCO et al.
first recurrence is highly statistically significant in terms of
the median concentrations of ER and PR in relation to the
site of the first recurrence. The higher the concentrations of
ER and PR, the more likely it is that the first recurrence will
be in bone, whereas the lower the concentrations are, the
higher the possibility of visceral metastases. Accordingly, the
relationship between sex steroid hormone receptors and the
first site of metastases not only depends on the presence or
absence of receptors but seems to be closely dependent on
the amounts of these receptors present.
DNA ploidy evaluation of the primary tumour has proved
to be a useful indicator for predicting the prognosis in
patients with breast cancer (Hedley et al., 1984; Cornelisse et
al., 1987; Kallioniemi et al., 1987). The proportion of
patients in this study with DNA diploid tumours who
developed metastases in the course of their disease is
significantly lower (29%) than that of patients with DNA
aneuploid tumours (57%). Measurement of the DNA ploidy
of the primary tumour is less useful, however, when related
to the first site of recurrence, for the proportions of cases
with DNA diploid tumours and DNA aneuploid tumours
were similar regardless ofthe site of the first recurrenece. Nor
do the survival curves show any differences between the
groups.
Histological grading emerges in this study as a predictive
variable, as was expected. However, the distribution of his-
tological grades in the data set is not equal. The majority of
the cases had histological grade III tumours, which have a
high malignant potential, and account for the majority of the
recurrent cases in breast cancer.
Multivariate analysis points to the same variables, his-
tological grading, disease free-interval and site of recurrence,
as the most valuable predictive factors in recurrent breast
cancer. However, female sex steroid receptors also appear to
have a specific role in recurrent breast cancer. Ploidy assess-
ment, on the contrary, contributes less to the understanding
of recurrent breast cancer.
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